Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
Identifieur interne : 000565 ( Main/Exploration ); précédent : 000564; suivant : 000566Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
Auteurs : Iwein Gyselinck [Belgique] ; Laurens Liesenborghs [Belgique] ; Ewout Landeloos [Belgique] ; Ann Belmans [Belgique] ; Geert Verbeke [Belgique] ; Peter Verhamme [Belgique] ; Robin Vos [Belgique] ; W. Janssens [Belgique]Source :
- Trials [ 1745-6215 ] ; 2021.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Antiviraux (administration et posologie), Antiviraux (effets indésirables), Azithromycine (administration et posologie), Azithromycine (effets indésirables), Belgique (épidémiologie), Durée du séjour (MeSH), Essais contrôlés randomisés comme sujet (MeSH), Femelle (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Jeune adulte (MeSH), Mâle (MeSH), Norme de soins (MeSH), Réaction de polymérisation en chaîne (MeSH), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Étude de validation de principe (MeSH), Études multicentriques comme sujet (MeSH).
- MESH :
- administration et posologie : Antiviraux, Azithromycine.
- effets indésirables : Antiviraux, Azithromycine.
- usage thérapeutique : Hydroxychloroquine.
- épidémiologie : Belgique.
- Adolescent, Adulte, Adulte d'âge moyen, Durée du séjour, Essais contrôlés randomisés comme sujet, Femelle, Humains, Jeune adulte, Mâle, Norme de soins, Réaction de polymérisation en chaîne, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Étude de validation de principe, Études multicentriques comme sujet.
- Wicri :
- geographic : Belgique.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Azithromycin (administration & dosage), Azithromycin (adverse effects), Belgium (epidemiology), COVID-19 (drug therapy), COVID-19 (epidemiology), COVID-19 (virology), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Length of Stay (MeSH), Male (MeSH), Middle Aged (MeSH), Multicenter Studies as Topic (MeSH), Polymerase Chain Reaction (MeSH), Proof of Concept Study (MeSH), Randomized Controlled Trials as Topic (MeSH), SARS-CoV-2 (genetics), Standard of Care (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Antiviral Agents, Azithromycin.
- chemical , adverse effects : Antiviral Agents, Azithromycin.
- geographic , epidemiology : Belgium.
- drug therapy : COVID-19.
- epidemiology : COVID-19.
- genetics : SARS-CoV-2.
- chemical , therapeutic use : Hydroxychloroquine.
- virology : COVID-19.
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Length of Stay, Male, Middle Aged, Multicenter Studies as Topic, Polymerase Chain Reaction, Proof of Concept Study, Randomized Controlled Trials as Topic, Standard of Care, Treatment Outcome, Young Adult.
Abstract
BACKGROUND
The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide antibiotic, known for its immunomodulatory properties. It has shown antiviral effect specifically against SARS-CoV-2 in vitro and acts on cytokine signaling pathways that have been implicated in COVID-19.
METHODS
DAWn-AZITHRO is a randomized, open-label, phase 2 proof-of-concept, multicenter clinical trial, evaluating the safety and efficacy of azithromycin for treating hospitalized patients with COVID-19. It is part of a series of trials testing promising interventions for COVID-19, running in parallel and grouped under the name DAWn-studies. Patients hospitalized on dedicated COVID wards are eligible for study inclusion when they are symptomatic (i.e., clinical or radiological signs) and have been diagnosed with COVID-19 within the last 72 h through PCR (nasopharyngeal swab or bronchoalveolar lavage) or chest CT scan showing typical features of COVID-19 and without alternate diagnosis. Patients are block-randomized (9 patients) with a 2:1 allocation to receive azithromycin plus standard of care versus standard of care alone. Standard of care is mostly supportive, but may comprise hydroxychloroquine, up to the treating physician's discretion and depending on local policy and national health regulations. The treatment group receives azithromycin qd 500 mg during the first 5 consecutive days after inclusion. The trial will include 284 patients and recruits from 15 centers across Belgium. The primary outcome is time from admission (day 0) to life discharge or to sustained clinical improvement, defined as an improvement of two points on the WHO 7-category ordinal scale sustained for at least 3 days.
DISCUSSION
The trial investigates the urgent and still unmet global need for drugs that may impact the disease course of COVID-19. It will either provide support or else justify the discouragement of the current widespread, uncontrolled use of azithromycin in patients with COVID-19. The analogous design of other parallel trials of the DAWN consortium will amplify the chance of identifying successful treatment strategies and allow comparison of treatment effects within an identical clinical context.
TRIAL REGISTRATION
EU Clinical trials register EudraCT Nb 2020-001614-38 . Registered on 22 April 2020.
DOI: 10.1186/s13063-021-05033-x
PubMed: 33563325
PubMed Central: PMC7871018
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.</title><author><name sortKey="Gyselinck, Iwein" sort="Gyselinck, Iwein" uniqKey="Gyselinck I" first="Iwein" last="Gyselinck">Iwein Gyselinck</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium. iwein.gyselinck@kuleuven.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Liesenborghs, Laurens" sort="Liesenborghs, Laurens" uniqKey="Liesenborghs L" first="Laurens" last="Liesenborghs">Laurens Liesenborghs</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Landeloos, Ewout" sort="Landeloos, Ewout" uniqKey="Landeloos E" first="Ewout" last="Landeloos">Ewout Landeloos</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Belmans, Ann" sort="Belmans, Ann" uniqKey="Belmans A" first="Ann" last="Belmans">Ann Belmans</name><affiliation wicri:level="1"><nlm:affiliation>Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Verbeke, Geert" sort="Verbeke, Geert" uniqKey="Verbeke G" first="Geert" last="Verbeke">Geert Verbeke</name><affiliation wicri:level="1"><nlm:affiliation>Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Verhamme, Peter" sort="Verhamme, Peter" uniqKey="Verhamme P" first="Peter" last="Verhamme">Peter Verhamme</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Vos, Robin" sort="Vos, Robin" uniqKey="Vos R" first="Robin" last="Vos">Robin Vos</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Janssens, W" sort="Janssens, W" uniqKey="Janssens W" first="W" last="Janssens">W. Janssens</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33563325</idno><idno type="pmid">33563325</idno><idno type="doi">10.1186/s13063-021-05033-x</idno><idno type="pmc">PMC7871018</idno><idno type="wicri:Area/Main/Corpus">000359</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000359</idno><idno type="wicri:Area/Main/Curation">000359</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000359</idno><idno type="wicri:Area/Main/Exploration">000359</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.</title><author><name sortKey="Gyselinck, Iwein" sort="Gyselinck, Iwein" uniqKey="Gyselinck I" first="Iwein" last="Gyselinck">Iwein Gyselinck</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium. iwein.gyselinck@kuleuven.be.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Liesenborghs, Laurens" sort="Liesenborghs, Laurens" uniqKey="Liesenborghs L" first="Laurens" last="Liesenborghs">Laurens Liesenborghs</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Landeloos, Ewout" sort="Landeloos, Ewout" uniqKey="Landeloos E" first="Ewout" last="Landeloos">Ewout Landeloos</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Belmans, Ann" sort="Belmans, Ann" uniqKey="Belmans A" first="Ann" last="Belmans">Ann Belmans</name><affiliation wicri:level="1"><nlm:affiliation>Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Verbeke, Geert" sort="Verbeke, Geert" uniqKey="Verbeke G" first="Geert" last="Verbeke">Geert Verbeke</name><affiliation wicri:level="1"><nlm:affiliation>Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Verhamme, Peter" sort="Verhamme, Peter" uniqKey="Verhamme P" first="Peter" last="Verhamme">Peter Verhamme</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Vos, Robin" sort="Vos, Robin" uniqKey="Vos R" first="Robin" last="Vos">Robin Vos</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Janssens, W" sort="Janssens, W" uniqKey="Janssens W" first="W" last="Janssens">W. Janssens</name><affiliation wicri:level="1"><nlm:affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author></analytic><series><title level="j">Trials</title><idno type="eISSN">1745-6215</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Azithromycin (administration & dosage)</term><term>Azithromycin (adverse effects)</term><term>Belgium (epidemiology)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (epidemiology)</term><term>COVID-19 (virology)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Length of Stay (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Multicenter Studies as Topic (MeSH)</term><term>Polymerase Chain Reaction (MeSH)</term><term>Proof of Concept Study (MeSH)</term><term>Randomized Controlled Trials as Topic (MeSH)</term><term>SARS-CoV-2 (genetics)</term><term>Standard of Care (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (effets indésirables)</term><term>Azithromycine (administration et posologie)</term><term>Azithromycine (effets indésirables)</term><term>Belgique (épidémiologie)</term><term>Durée du séjour (MeSH)</term><term>Essais contrôlés randomisés comme sujet (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Norme de soins (MeSH)</term><term>Réaction de polymérisation en chaîne (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Étude de validation de principe (MeSH)</term><term>Études multicentriques comme sujet (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Azithromycin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Azithromycin</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Belgium</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Azithromycine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Azithromycine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Belgique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Length of Stay</term><term>Male</term><term>Middle Aged</term><term>Multicenter Studies as Topic</term><term>Polymerase Chain Reaction</term><term>Proof of Concept Study</term><term>Randomized Controlled Trials as Topic</term><term>Standard of Care</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Durée du séjour</term><term>Essais contrôlés randomisés comme sujet</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Norme de soins</term><term>Réaction de polymérisation en chaîne</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Étude de validation de principe</term><term>Études multicentriques comme sujet</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Belgique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide antibiotic, known for its immunomodulatory properties. It has shown antiviral effect specifically against SARS-CoV-2 in vitro and acts on cytokine signaling pathways that have been implicated in COVID-19.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>DAWn-AZITHRO is a randomized, open-label, phase 2 proof-of-concept, multicenter clinical trial, evaluating the safety and efficacy of azithromycin for treating hospitalized patients with COVID-19. It is part of a series of trials testing promising interventions for COVID-19, running in parallel and grouped under the name DAWn-studies. Patients hospitalized on dedicated COVID wards are eligible for study inclusion when they are symptomatic (i.e., clinical or radiological signs) and have been diagnosed with COVID-19 within the last 72 h through PCR (nasopharyngeal swab or bronchoalveolar lavage) or chest CT scan showing typical features of COVID-19 and without alternate diagnosis. Patients are block-randomized (9 patients) with a 2:1 allocation to receive azithromycin plus standard of care versus standard of care alone. Standard of care is mostly supportive, but may comprise hydroxychloroquine, up to the treating physician's discretion and depending on local policy and national health regulations. The treatment group receives azithromycin qd 500 mg during the first 5 consecutive days after inclusion. The trial will include 284 patients and recruits from 15 centers across Belgium. The primary outcome is time from admission (day 0) to life discharge or to sustained clinical improvement, defined as an improvement of two points on the WHO 7-category ordinal scale sustained for at least 3 days.</p></div><div type="abstract" xml:lang="en"><p><b>DISCUSSION</b></p><p>The trial investigates the urgent and still unmet global need for drugs that may impact the disease course of COVID-19. It will either provide support or else justify the discouragement of the current widespread, uncontrolled use of azithromycin in patients with COVID-19. The analogous design of other parallel trials of the DAWN consortium will amplify the chance of identifying successful treatment strategies and allow comparison of treatment effects within an identical clinical context.</p></div><div type="abstract" xml:lang="en"><p><b>TRIAL REGISTRATION</b></p><p>EU Clinical trials register EudraCT Nb 2020-001614-38 . Registered on 22 April 2020.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33563325</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>09</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.</ArticleTitle><Pagination><MedlinePgn>126</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-021-05033-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide antibiotic, known for its immunomodulatory properties. It has shown antiviral effect specifically against SARS-CoV-2 in vitro and acts on cytokine signaling pathways that have been implicated in COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">DAWn-AZITHRO is a randomized, open-label, phase 2 proof-of-concept, multicenter clinical trial, evaluating the safety and efficacy of azithromycin for treating hospitalized patients with COVID-19. It is part of a series of trials testing promising interventions for COVID-19, running in parallel and grouped under the name DAWn-studies. Patients hospitalized on dedicated COVID wards are eligible for study inclusion when they are symptomatic (i.e., clinical or radiological signs) and have been diagnosed with COVID-19 within the last 72 h through PCR (nasopharyngeal swab or bronchoalveolar lavage) or chest CT scan showing typical features of COVID-19 and without alternate diagnosis. Patients are block-randomized (9 patients) with a 2:1 allocation to receive azithromycin plus standard of care versus standard of care alone. Standard of care is mostly supportive, but may comprise hydroxychloroquine, up to the treating physician's discretion and depending on local policy and national health regulations. The treatment group receives azithromycin qd 500 mg during the first 5 consecutive days after inclusion. The trial will include 284 patients and recruits from 15 centers across Belgium. The primary outcome is time from admission (day 0) to life discharge or to sustained clinical improvement, defined as an improvement of two points on the WHO 7-category ordinal scale sustained for at least 3 days.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The trial investigates the urgent and still unmet global need for drugs that may impact the disease course of COVID-19. It will either provide support or else justify the discouragement of the current widespread, uncontrolled use of azithromycin in patients with COVID-19. The analogous design of other parallel trials of the DAWN consortium will amplify the chance of identifying successful treatment strategies and allow comparison of treatment effects within an identical clinical context.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">EU Clinical trials register EudraCT Nb 2020-001614-38 . Registered on 22 April 2020.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gyselinck</LastName><ForeName>Iwein</ForeName><Initials>I</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-4068-7228</Identifier><AffiliationInfo><Affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium. iwein.gyselinck@kuleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liesenborghs</LastName><ForeName>Laurens</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landeloos</LastName><ForeName>Ewout</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belmans</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verbeke</LastName><ForeName>Geert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vos</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssens</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>DAWn-Azithro consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Trials. 2021 Mar 5;22(1):187</RefSource><PMID Version="1">33673831</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075082" MajorTopicYN="N">Proof of Concept Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059039" MajorTopicYN="Y">Standard of Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral</Keyword><Keyword MajorTopicYN="N">Azithromycin</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Macrolide</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Janssens</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vos</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gyselinck</LastName><ForeName>Iwein</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderhelst</LastName><ForeName>Eef</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouckaert</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Mayer</LastName><ForeName>Nikolaas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papleux</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soenen</LastName><ForeName>Ann-Catherine</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Derweduwe</LastName><ForeName>Aurelie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vandeurzen</LastName><ForeName>Kurt</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinot</LastName><ForeName>Jean-Benoît</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goeminne</LastName><ForeName>Pieter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pilette</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schildermans</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decoster</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>08</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>01</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>10</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33563325</ArticleId><ArticleId IdType="doi">10.1186/s13063-021-05033-x</ArticleId><ArticleId IdType="pii">10.1186/s13063-021-05033-x</ArticleId><ArticleId IdType="pmc">PMC7871018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu Y, Yan L, Wan L, Xiang T, Le A, Liu J, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20(June):656–7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30232-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4 Lancet Publishing Group.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-47. https://doi.org/10.1111/jth.14768 .</Citation></Reference><Reference><Citation>Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘ cytokine storm ’ in COVID-19. J Inf Secur. 2020;80:607–13.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8 Available from: https://pubmed.ncbi.nlm.nih.gov/32142651 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19; 2020. p. 726–30.</Citation></Reference><Reference><Citation>Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9. https://doi.org/10.1111/jth.14817 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14817</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden S, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020.</Citation></Reference><Reference><Citation>Bakheit AHH, Al-Hadiya BMH, Abd-Elgalil AA. Azithromycin. In: Profiles of drug substances, excipients and related methodology, vol. 39. 1st ed; 2014. p. 1–40.</Citation></Reference><Reference><Citation>Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. 2012;68(5):479–503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-011-1161-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamura K, Ichikado K, Takaki M, Sakata Y, Yasuda Y, Shingu N, et al. Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis. Springerplus. 2016 [cited 2020 Dec 4];5(1):1–7. https://doi.org/10.1186/s40064-016-2866-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40064-016-2866-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzel M, Akbarshahi H, Bjermer L, Uller L. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. Sci Rep. 2016;6(June):1–11.</Citation></Reference><Reference><Citation>Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3):646–54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00095809</ArticleId></ArticleIdList></Reference><Reference><Citation>Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediat Inflamm. 2012;2012:1–9.</Citation></Reference><Reference><Citation>Porter JD, Watson J, Roberts LR, Gill SK, Groves H, Dhariwal J, et al. Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN-augmenting activity in airway epithelium. J Antimicrob Chemother. 2016;71(10):2767–81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkw222</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Zu S, Deng YQ, Li D, Parvatiyar K, Quanquin N, et al. Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses. Antimicrob Agents Chemother. 2019;63(12)1–14.</Citation></Reference><Reference><Citation>Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et al. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2016;1(7):317–26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.5b00030</ArticleId></ArticleIdList></Reference><Reference><Citation>Touret F, Gilles M, Barral K, Nougairède A, van Helden J, Decroly E, et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep. 2020;10(1):1–8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70143-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-99. https://doi.org/10.1056/NEJMoa2001282 .</Citation></Reference><Reference><Citation>Kahan BC, Jairath V, Doré CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials. 2014;15(1):1–7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6215-15-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB. Multiple imputation for nonresponse in surveys [Internet]. In: Rubin DB, editor. Wiley Series in Probability and Statistics. Hoboken: Wiley; 1987 [cited 2020 Dec 4]. https://doi.org/10.1002/9780470316696 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470316696</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo D, Cai Y, Chai D, Liang B, Bai N, Wang R. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65(9):631–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">21038838</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents. 2001;18(18):71–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0924-8579(01)00397-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms. Front Immunol. 2018;9(302):1–14. Available from: https://pubmed.ncbi.nlm.nih.gov/29593707 .</Citation></Reference><Reference><Citation>Di Paolo A, Barbara C, Chella A, Angeletti CA, Del Tacca M. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol Res. 2002;46(6):545–50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1043661802002384</ArticleId></ArticleIdList></Reference><Reference><Citation>Danesi R, Lupetti A, Barbara C, Ghelardi E, Chella A, Malizia T, et al. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J Antimicrob Chemother. 2003;51(4):939–45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkg138</ArticleId></ArticleIdList></Reference><Reference><Citation>Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2019;200(7):E45–67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201908-1581ST</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HC, Kang SH. Total synthesis of azithromycin. Angew Chem Int Ed. 2009 [cited 2020 Dec 4];48(10):1827–9. https://doi.org/10.1002/anie.200805334 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.200805334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li></country></list><tree><country name="Belgique"><noRegion><name sortKey="Gyselinck, Iwein" sort="Gyselinck, Iwein" uniqKey="Gyselinck I" first="Iwein" last="Gyselinck">Iwein Gyselinck</name></noRegion><name sortKey="Belmans, Ann" sort="Belmans, Ann" uniqKey="Belmans A" first="Ann" last="Belmans">Ann Belmans</name><name sortKey="Janssens, W" sort="Janssens, W" uniqKey="Janssens W" first="W" last="Janssens">W. Janssens</name><name sortKey="Landeloos, Ewout" sort="Landeloos, Ewout" uniqKey="Landeloos E" first="Ewout" last="Landeloos">Ewout Landeloos</name><name sortKey="Liesenborghs, Laurens" sort="Liesenborghs, Laurens" uniqKey="Liesenborghs L" first="Laurens" last="Liesenborghs">Laurens Liesenborghs</name><name sortKey="Verbeke, Geert" sort="Verbeke, Geert" uniqKey="Verbeke G" first="Geert" last="Verbeke">Geert Verbeke</name><name sortKey="Verhamme, Peter" sort="Verhamme, Peter" uniqKey="Verhamme P" first="Peter" last="Verhamme">Peter Verhamme</name><name sortKey="Vos, Robin" sort="Vos, Robin" uniqKey="Vos R" first="Robin" last="Vos">Robin Vos</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000565 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000565 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33563325
|texte= Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33563325" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |